• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Rare Diseases

    Agios Advances Mitapivat Toward SCD Accelerated Approval

    GLOBENEWSWIRE

    Agios Details 2026 Strategy To Boost Rare Disease Portfolio

    GLOBENEWSWIRE

    FDA Approves Agios` AQVESME For Anemia In Adult Thalassemia

    GLOBENEWSWIRE

    Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

    GLOBENEWSWIRE

    Agios’ Pyrukynd turns in mixed results in sickle cell ph. 3

    GLOBENEWSWIRE

    Agios’ Pyrukynd turns in mixed results in sickle cell ph. 3

    GLOBENEWSWIRE

    Agios To Unveil Mitapivat Data In Rare Blood Disorders

    GLOBENEWSWIRE

    Agios` Mitapivat Gets CHMP Nod For Adult with Thalassemia

    GLOBENEWSWIRE

    Avanzanite Partner Agio Receives Positive Opinion for Pyrukynd

    PHARMIWEB

    Agios Updates U.S. PDUFA for Pyruknd in Thalassemia

    GLOBENEWSWIRE

    Agios Wins Saudi Approval for Pyrukynd in Adult Thalassemia

    GLOBENEWSWIRE

    Avanzanite partners Agios to launch Pyrukynd in Europe

    BUSINESSWIRE

    Agios’ Ph 3 Activate-Kids Hits Primary Endpoint In PK Deficiency

    GLOBENEWSWIRE

    Agios Announces 2025 Milestones For Rare Disease Portfolio

    GLOBENEWSWIRE

    FDA Accepts Agios PYRUKYND NDA For Alpha, Beta-Thalassemia Patients

    GLOBENEWSWIRE

    Europe Grants Orphan Status for Mitapivat in Sickle Cell

    GLOBENEWSWIRE

    Agios Presents New Data on Mitapivat & Tebapivat at ASH 2024

    GLOBENEWSWIRE

    Agios Reports Business Highlights and Q3 2024 Financial Results

    GLOBENEWSWIRE

    Agios To Present At Cantor Global Healthcare Conference

    GLOBENEWSWIRE

    Agios Reports Business Highlights and Second Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Agios Announces Phase 3 ACTIVATE-KidsT Study Results

    GLOBENEWSWIRE

    Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

    GLOBENEWSWIRE

    Agios to Present Broad Set of Translational Data in Rare Blood Disorders

    GLOBENEWSWIRE

    Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.